Atopic Dermatitis Player Arcutis Scoops Up DucentisBioTherapeutics

  • Arcutis Biotherapeutics Inc ARQT has agreed to acquire LifeArc's portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases.
  • The agreement values Ducentis at up to $400 million, including an upfront cash payment of $16 million, Arcutis stock valued at approximately $14 million, and future contingent payments based on development and commercial success. 
  • Ducentis' lead pre-clinical asset, DS-234, is being developed for atopic dermatitis. 
  • DS-234 is a fusion protein that is a highly selective and potent agonist of CD200R, an immune-regulatory receptor thought to be an essential immunological checkpoint with a pivotal role in maintaining immune tolerance.
  • "Ducentis' DS-234 fits in well with our strategy of developing best-in-class molecules against biologically-validated targets and is highly complementary to roflumilast cream as another potential innovative treatment option," said Frank Watanabe, Arcutis' President & CEO.
  • Recently, Arcutis completed enrollment in its INTEGUMENT-2 and INTEGUMENT-1 Phase 3 trials of roflumilast for Atopic dermatitis. Topline data readout from both trials is expected by the end of this year.
  • Price Action: ARQT shares are up 2.37% at $22.05 on the last check Thursday.
Posted In: BiotechM&ANewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!